Nail Psoriasis: A Review of Treatment Options

被引:94
作者
Pasch, Marcel C. [1 ]
机构
[1] Radboud Univ Nijmegen, Med Ctr, Dept Dermatol, POB 9101, NL-6500 HB Nijmegen 370, Netherlands
关键词
SEVERE PLAQUE PSORIASIS; PULSED DYE-LASER; QUALITY-OF-LIFE; ORAL PHOSPHODIESTERASE-4 INHIBITOR; MONOCLONAL-ANTIBODY IXEKIZUMAB; TAZAROTENE 0.1-PERCENT GEL; TO-SEVERE PSORIASIS; DOUBLE-BLIND; PHASE-III; BETAMETHASONE DIPROPIONATE;
D O I
10.1007/s40265-016-0564-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Nail involvement affects 80-90 % of patients with plaque psoriasis, and is even more prevalent in patients with psoriatic arthritis. This review is the result of a systemic approach to the literature and covers topical, intralesional, conventional systemic, and biologic systemic treatments, as well as non-pharmacological treatment options for nail psoriasis. The available evidence suggests that all anti-tumor necrosis factor-a, anti-interleukin (IL)-17, and anti-IL-12/23 antibodies which are available for plaque psoriasis and psoriatic arthritis are highly effective treatments for nail psoriasis. Conventional systemic treatments, including methotrexate, cyclosporine, acitretin, and apremilast, as well as intralesional corticosteroids, can also be effective treatments for nail psoriasis. Topical treatments, including corticosteroids, calcipotriol, tacrolimus, and tazarotene, have also been shown to have a position in the treatment of nail psoriasis, particularly in mild cases. Finally, non-pharmacological treatment options, including phototherapy, photodynamic therapy, laser therapy, and several radiotherapeutic options, are also reviewed but cannot be advised as first-line treatment options. Another conclusion of this review is that the lack of a reliable core set of outcomes measures for trials in nail psoriasis hinders the interpretation of results, and is urgently needed.
引用
收藏
页码:675 / 705
页数:31
相关论文
共 166 条
  • [1] ABELL E, 1973, BRIT J DERMATOL, V89, P191
  • [2] Al-Mutairi Ahmed, 2013, Indian J Dermatol, V58, P243, DOI 10.4103/0019-5154.110864
  • [3] Onychomycosis in patients of nail psoriasis on biologic therapy: a randomized, prospective open label study comparing Etanercept, Infliximab and Adalimumab
    Al-Mutairi, Nawaf
    Nour, Tarek
    Al-Rqobah, Duha
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2013, 13 (05) : 625 - 629
  • [4] [Anonymous], 2013, COCHRANE DATABASE SY
  • [5] RESPONSE OF NAIL PSORIASIS TO CYCLOSPORINE
    ARNOLD, WP
    GERRITSEN, MJP
    VANDEKERKHOF, PCM
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 1993, 129 (06) : 750 - 751
  • [6] Evaluation of a novel 308-nm monochromatic excimer light delivery system in dermatology: a pilot study in different chronic localized dermatoses
    Aubin, F
    Vigan, M
    Puzenat, E
    Blanc, D
    Drobacheff, C
    Deprez, P
    Humbert, P
    Laurent, R
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2005, 152 (01) : 99 - 103
  • [7] Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes
    Augustin, M.
    Blome, C.
    Costanzo, A.
    Dauden, E.
    Ferrandiz, C.
    Girolomoni, G.
    Gniadecki, R.
    Iversen, L.
    Menter, A.
    Michaelis-Wittern, K.
    Morita, A.
    Nakagawa, H.
    Reich, K.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2014, 170 (03) : 591 - 598
  • [8] Topical treatment of nail psoriasis with a new corticoid-containing nail lacquer formulation
    Baran, R
    Tosti, A
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 1999, 10 (03) : 201 - 204
  • [9] Bardazzi F, 2013, J DTSCH DERMATOL GES, V11, P1065, DOI [10.1111/ddg.12230, 10.1111/ddg.12173]
  • [10] Leflunomide in Psoriatic Arthritis: Results From a Large European Prospective Observational Study
    Behrens, Frank
    Finkenwirth, Christoph
    Pavelka, Karel
    Stolfa, Jiri
    Sipek-Dolnicar, Alenka
    Thaci, Diamant
    Burkhardt, Harald
    [J]. ARTHRITIS CARE & RESEARCH, 2013, 65 (03) : 464 - 470